LIPOCINE SHAREHOLDERS HAVE AN OPPORTUNITY TO RECOVER THEIR INVESTMENT LOSSES CLICK HERE TO VIEW THE FIRM RÉSUMÉ OF BERNSTEIN LIEBHARD LLP.

Lipocine Inc.

Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired shares of Lipocine Inc. (“Lipocine” or the “Company”) (NASDAQ: LPCN) from March 27, 2019 to November 8, 2019, inclusive (the “Class Period”).

If you purchased Lipocine securities, and/or would like to discuss your legal rights and options, please click “Join Class Action” above. 

New York, New York — Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired shares of Lipocine Inc. (“Lipocine” or the “Company”) (NASDAQ: LPCN) from March 27, 2019 to November 8, 2019, inclusive (the “Class Period”). The lawsuit filed in the United States District Court for the District of Utah alleges violations of the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the results from Lipocines clinical studies of TLANDO were insufficient to demonstrate the drugs efficacy; (ii) accordingly, Lipocines third NDA for TLANDO was highly likely to be found deficient by the FDA; and (iii) as a result, the Companys public statements were materially false and misleading at all relevant times.

On November 11, 2019, Lipocine issued a press release announcing receipt of a CRL from the FDA regarding its NDA for TLANDO. In the press release, Lipocine advised investors that the FDA had again rejected the NDA for TLANDOthis time because an efficacy trial had not met three of its secondary endpoints. On this news, Lipocines stock price fell $1.93 per share, or 70.7%, to close at $0.80 per share on November 11, 2019.

If you wish to serve as lead plaintiff, you must move the Court no later than January 14, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2019 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information

Matthew E. Guarnero Bernstein Liebhard LLP https://www.bernlieb.com (877) 779-1414 MGuarnero@bernlieb.com